Peptide having angiogenesis inhibitory activity and composition containing same

• US 10,034,922 B2
• Filed: 11/21/2014
• Issued: 07/31/2018
• Est. Priority Date: 11/22/2013
• Status: Active Grant

• Current Assignee: Gemvax & Kael Co., Ltd., Sang Jae Kim
• Original Assignee: Gemvax & Kael Co., Ltd.
• Inventors: Kim, Sang Jae
• Primary Examiner(s): Ha, Julie
• Application Number:
  US15/038,269
• Publication Number:
  US 20160296604A1
• Time in Patent Office: 1,348 Days
• Field of Search: 514 214, 514 133
• CPC Class Codes: A23L 33/17 Amino acids, peptides or proteins
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/45 Transferases (2)
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 9/1276 : RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
• CPC Class Codes: C12Y 207/07049 : RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Abstract

A peptide having angiogenesis inhibition activity and pharmaceutical composition comprising thereof is described. More specifically, the application relates to the pharmaceutical composition for inhibiting angiogenesis comprising the peptide as a peptide derived from telomerase.

Claims

1. A method for treating an angiogenesis-related disease comprising administering to a subject in need thereof the isolated peptide of SEQ ID NO:

1, wherein the angiogenesis-related disease is selected from a group consisting of metastasis, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, scarlet syndrome, proliferative retinopathy, psoriasis, macular degeneration, hemophilic arthropathy, capillary proliferation within atherosclerotic plaques, keloid, wound granulation, vascular adhesion, rheumatoid arthritis, chronic inflammation, osteoarthritis, autoimmune disease, Crohn'"'"'s disease, restenosis, atherosclerosis, stenosis of intestine, cat scratch disease, ulcers, cirrhosis complications, glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic micro vascular syndrome, organ transplant rejection, glomerulopathy, diabetes, uncontrolled angiogenesis-related disorders, diseases of inflammation and neurodegeneration.

2. The method according to claim 1, wherein the peptide is administered in a single dose at a concentration of 10 ng/kg to 10 mg/kg.

3. The method according to claim 1, wherein the peptide is administered 1 to 3 times a day.

4. The method of claim 1, wherein the peptide is administered at a daily dose of 10 ng/kg to 10 mg/kg.

5. A method for treating an angiogenesis-related disease comprising administering to a subject in need thereof a composition comprising the isolated peptide of SEQ ID NO:

1, wherein the angiogenesis-related disease is selected from a group consisting of metastasis, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, scarlet syndrome, proliferative retinopathy, psoriasis, macular degeneration, hemophilic arthropathy, capillary proliferation within atherosclerotic plaques, keloid, wound granulation, vascular adhesion, rheumatoid arthritis, chronic inflammation, osteoarthritis, autoimmune disease, Crohn'"'"'s disease, restenosis, atherosclerosis, stenosis of intestine, cat scratch disease, ulcers, cirrhosis complications, glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic micro vascular syndrome, organ transplant rejection, glomerulopathy, diabetes, uncontrolled angiogenesis-related disorders, diseases of inflammation and neurodegeneration.

6. The method according to claim 5, wherein the angiogenesis-related disease is metastasis.

7. The method according to claim 5, wherein the composition is a pharmaceutical composition.

8. The method according to claim 5, wherein the composition is a food composition.

9. The method of claim 5, wherein the composition is administered through oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, in the bone marrow, epidural, or subcutaneous routes.

10. The method of claim 5, wherein the composition comprises 0.01 g/L to 1 kg/L of the isolated peptide.

11. The method of claim 5, wherein the peptide is administered in a single dose at a concentration of 10 ng/kg to 10 mg/kg.

12. The method of claim 5, wherein the peptide is administered 1 to 3 times a day.

13. The method of claim 5, wherein the peptide is administered at a daily dose of 10 ng/kg to 10 mg/kg.

14. The method according to claim 5, wherein the method inhibits proliferation of vascular endothelial cells, VEGF (Vascular endothelial growth factor)-induced tube formation and invasion of vascular endothelial cells.

15. The method according to claim 5, wherein the composition inhibits proliferation of vascular endothelial cells or tube formation.

16. The method according to claim 5, wherein the composition inhibits the proliferation of vascular endothelial cells by VEGF-A (Vascular endothelial growth factor-A), the tube formation, or the invasion of vascular endothelial cell.